What's everyone's take on this paragraph?
'The Company is also refocussing its medicinal cannabis and pharmaceuticals manufacturing strategy towards contract high value pharmaceutical manufacturing instead of looking to primarily develop Canndeo as a brand. This pivot should enable the Company to attract new global clients looking for a TGA and EU GMP manufacturer without the perception that the Company may be competing with its prospective clients’ brands in the market.'My understanding is Canndeo is to be discontinued so as not to compete with any potential contracts acquired. I assume they'll sell what stock they'll sell what stock they have and produce no more. Thoughts?
Ann: Quarterly Update and Appendix 4C, page-20
Add EPN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.208M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| EPN (ASX) Chart |
Day chart unavailable